Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15623716.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
Medical subject headings
- Creutzfeldt-Jakob Syndrome
- Quinacrine